The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2025 | An analysis of PRO data from the BRUIN trial
Catherine Coombs, MD, UC Irvine Health, Orange County, CA, discusses the findings from an analysis of patient-reported outcome (PRO) data from the Phase I/II BRUIN study (NCT03740529). Dr Coombs highlights that the majority of patients experienced either stable or improved quality of life when treated with pirtobrutinib, further supporting its use in the setting of relapsed chronic lymphocytic leukemia (CLL). This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2025 in Krakow, Poland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I’ll be presenting data also from the Phase I/II BRUIN trial, which as a reminder was the trial that led to the accelerated approval of pirtobrutinib in the United States. It was a large study that was focused on the CLL patient population, but the poster will be reviewing the patient reported outcomes for this trial. And so of course, patient reported outcomes are hugely important because you could have a very efficacious drug, but if it makes someone miserable, well, that’s not really a success, especially in a chronic disease like CLL...
I’ll be presenting data also from the Phase I/II BRUIN trial, which as a reminder was the trial that led to the accelerated approval of pirtobrutinib in the United States. It was a large study that was focused on the CLL patient population, but the poster will be reviewing the patient reported outcomes for this trial. And so of course, patient reported outcomes are hugely important because you could have a very efficacious drug, but if it makes someone miserable, well, that’s not really a success, especially in a chronic disease like CLL. And so fortunately, what the PRO data showed is that the majority of patients had either stable quality of life when treated with the drug or an improvement in their quality of life based on validated questionnaires. And so what this supports is the ongoing use of pirtobrutinib as a very well tolerated, in addition to what we already know, efficacious agent in the setting of relapsed CLL.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
AbbVie, AstraZeneca, BeOne Medicines, Lilly, Genentech, Janssen.
